Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Gurney

Showing results (91-100 of 135) with videos related to

Pageof 14
Sort By:
International Journal of Cancer|June 9, 2023
Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trialSun Young Rha, Toni K Choueiri, Vsevolod B Matveev, et al.
European Urology Oncology|May 3, 2026
Pembrolizumab Plus Lenvatinib in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort EMarinela Augustin, Brigitte Laguerre, Capucine Baldini, et al.
The Lancet. Oncology|June 10, 2022
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trialRobert J Motzer, Thomas Powles, Mauricio Burotto, et al.
European Urology|July 24, 2025
First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 TrialMartin H Voss, Howard Gurney, Vagif Atduev, et al.
European Urology|April 30, 2023
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 TrialPetros Grivas, Se Hoon Park, Eric Voog, et al.
European Urology Oncology|May 14, 2025
Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate CancerNobuaki Matsubara, Daniel Petrylak, Raffaele Ratta, et al.
European Urology|April 16, 2017
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025Bernard Escudier, Robert J Motzer, Padmanee Sharma, et al.
European Urology|June 4, 2025
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only DiseaseJoaquim Bellmunt, Thomas Powles, Se Hoon Park, et al.
ESMO Open|November 28, 2020
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trialLaurence Albiges, Nizar M Tannir, Mauricio Burotto, et al.
European Urology|August 22, 2024
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 TrialRonald de Wit, David J Vaughn, Yves Fradet, et al.
Pageof 14

Showing results (91-100 of 135) with videos related to

Sort By:
Pageof 14
International Journal of Cancer|June 9, 2023
Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trialSun Young Rha, Toni K Choueiri, Vsevolod B Matveev, et al.
European Urology Oncology|May 3, 2026
Pembrolizumab Plus Lenvatinib in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort EMarinela Augustin, Brigitte Laguerre, Capucine Baldini, et al.
The Lancet. Oncology|June 10, 2022
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trialRobert J Motzer, Thomas Powles, Mauricio Burotto, et al.
European Urology|July 24, 2025
First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 TrialMartin H Voss, Howard Gurney, Vagif Atduev, et al.
European Urology|April 30, 2023
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 TrialPetros Grivas, Se Hoon Park, Eric Voog, et al.
European Urology Oncology|May 14, 2025
Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate CancerNobuaki Matsubara, Daniel Petrylak, Raffaele Ratta, et al.
European Urology|April 16, 2017
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025Bernard Escudier, Robert J Motzer, Padmanee Sharma, et al.
European Urology|June 4, 2025
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only DiseaseJoaquim Bellmunt, Thomas Powles, Se Hoon Park, et al.
ESMO Open|November 28, 2020
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trialLaurence Albiges, Nizar M Tannir, Mauricio Burotto, et al.
European Urology|August 22, 2024
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 TrialRonald de Wit, David J Vaughn, Yves Fradet, et al.
Pageof 14